Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. reports on the Annual Meeting of Stockholders held on August 21, 2018. The company is incorporated in Delaware and is based in Melville, New York.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders approved several material amendments to the company's capital structure and equity plans:
- Common Stock Authorization: Increased from 30,000,000 to 75,000,000 shares (4,869,597 For; 85,769 Against).
- Preferred Stock Authorization: Increased from 5,000,000 to 20,000,000 shares (3,897,760 For; 37,834 Against).
- Equity Participation Plan: The 2010 Plan was amended to increase authorized shares from 4,250,000 to 10,000,000 (3,898,760 For; 36,834 Against).
- Director Elections: Class I directors Robert B. Catell and Charles S. Ryan were elected with significant support.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. The primary implication of the approved amendments is an increased capacity for future equity issuance, which may impact existing shareholder dilution.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment regarding the increased share authorization.
- Review the updated 2010 Equity Participation Plan to understand the terms of the additional 5,750,000 authorized shares.
- Monitor future filings for any immediate issuance of shares under the newly authorized limits.
- Confirm the impact of the increased preferred stock authorization on the company's capital structure hierarchy.